RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @antgiorda: That was the reason brought me to US for a PhD on CTC. Almost 10 years form my first step into MD Anderson, thank you @MCris…
That was the reason brought me to US for a PhD on CTC. Almost 10 years form my first step into MD Anderson, thank you @MCristofanill thank you Jim Reuben
LizDowling2: RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginning of liquid biopsy. https://t.co/bQA0svJi11
RT LizDowling2 "RT MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginning of liquid biopsy. https://t.co/3tAYNenY8r"
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
Seems like it would be obvious that a basic stain of a blood sample would reveal the same thing that an expensive liquid biopsy would say. In the meantime (during the biopsy procedure) tumor cells are setting up shop in the patients brain.
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
The levels of circulating tumor cells at baseline and at the first follow-up visit were the most significant predictors of progression-free and overall survival #liquidbiopsy
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
@cassis30206341 Hier ist endlich das Paper mit den CTC's. So wie ich das sehe, reicht es, wenn CYDY zeigen kann, dass sie ein >=5 pro 7.5ml CTC Level (deutlich) unter 5 senken können, weil das die Lebensdauer deutlich erhöht!
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
@isliquidbiopsy
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
#liquidbiopsy @isliquidbiopsy @MJOSESERRANO19 @jjdmochon
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
RT @MCristofanill: Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginn…
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | NEJM. 15 years after the beginning of liquid biopsy. https://t.co/IwxTmSx0pF
Hayes: CTC enumeration and prognosis: CTCs vast majority of data is from CellSearch.'04 ref https://t.co/PWekg21C3X mBC #AACR18
Lianidou: In Br ca - '04 NEJM https://t.co/kuwkU5pg3P 'seminal paper' for CellSearch, assoc'd with survival oin mBC #AACR18
Metastatic #breastcancer pts with elevated circulating tumor cells after 1 treatment cycle have rapid progression http://t.co/AMmWJCCHu3
Metastatic #breastcancer pts with elevated circulating tumor cells after 1 treatment cycle have rapid progression http://t.co/AMmWJCCHu3
@ChemoAdvisor this confirms findings first reported in 2004. http://t.co/Xh8ABoy0t7